newsfilter
← Latest News
PR Newswire·

Edgewise Therapeutics Unveils the Differentiated Mechanism of Action (MoA) of its Cardiac Sarcomere Modulator EDG-7500

  • Edgewise Therapeutics announced that its investigational drug EDG-7500 targets the Regulatory Light Chain (RLC) to improve cardiac relaxation while preserving systolic function in preclinical models.
  • Early clinical observations in patients with symptomatic hypertrophic cardiomyopathy (HCM) align with the positive preclinical data regarding EDG-7500's diastolic-biased profile.
  • A peer-reviewed publication describing EDG-7500's mechanism of action will be released on September 22, 2026, with a link available on the company's website.
  • The company hosted a webcast on September 22, 2026, at 8:30 a.m. Eastern Time to discuss the findings with management.
  • EDG-7500 is an oral, first-in-class cardiac sarcomere modulator being evaluated for obstructive & nonobstructive HCM.
  • The 12-week Phase 2 CIRRUS-HCM trial demonstrated that EDG-7500 was generally safe, well tolerated, & showed no clinically significant changes in left ventricular ejection fraction.
  • Edgewise Therapeutics expects to initiate a Phase 3 trial for EDG-7500 in the fourth quarter of 2026.